Gastric intestinal metaplasia: Prevalence in a large Australian center and nationwide survey of endoscopic practice

被引:0
作者
Hartley, Imogen [1 ]
Connoley, Declan [1 ]
Sane, Nikhita [1 ]
Hirsch, Ryan [1 ]
Abeywickrama, Dilini [1 ]
Sim, Nicholle [1 ]
Ea, Vinny [1 ]
Azzopardi, Robert [1 ]
Simpson, Ian [1 ]
Bell, Sally [1 ]
Hew, Simon [1 ]
机构
[1] Monash Hlth, Gastroenterol Dept, 246 Clayton Rd, Melbourne, Vic 3168, Australia
来源
JGH OPEN | 2024年 / 8卷 / 06期
关键词
atrophic gastritis; gastric adenocarcinoma; gastric intestinal metaplasia; HELICOBACTER-PYLORI INFECTION; CANCER;
D O I
10.1002/jgh3.13115
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimAtrophic gastritis (AG) and gastric intestinal metaplasia (GIM) are early changes in the stepwise progression to gastric adenocarcinoma. There is heterogeneity in international guidelines regarding the endoscopic diagnosis and surveillance of AG and GIM. This study aims to determine the prevalence of GIM in an Australian center and assess the approach of Australian endoscopists for these two conditions.MethodsWe conducted a single-center retrospective study of adult patients between January 2015 and December 2020 diagnosed with GIM on gastric biopsy following upper gastric endoscopy. A web-based, 25-question, investigator-designed, multiple-choice survey was distributed among all registered endoscopists in Australia.ResultsThe overall prevalence of GIM within a single Australian center was 11.7% over 5 years. Of the 1026 patients identified, only 58.7% underwent mapping biopsies using the modified Sydney protocol. Among the cohort, 1.6% had low-grade dysplasia, 0.9% had high-grade dysplasia, and 1.8% had malignancy on initial gastroscopy. Two hundred and sixty-seven (7.2%) endoscopists completed the survey, 44.2% indicated they would perform mapping for all patients, and 36% only for high-risk patients. Only 1.5% (n = 4) of respondents were able to correctly identify all six endoscopic photos of GIM/AG.ConclusionThis study demonstrates that in a large tertiary center, GIM is a prevalent endoscopic finding, but the associated rates of dysplasia and cancer were low. Additionally, among a small proportion of surveyed Australian endoscopists, there is notable variability in the endoscopic approach for AG and GIM and significant knowledge gaps. More training is required to increase the recognition of GIM and compliance with histological mapping. This retrospective study in a large Australian tertiary center revealed a gastric intestinal metaplasia (GIM) prevalence of 11.7% over 5 years, with low rates of associated dysplasia and malignancy. The survey of Australian endoscopists showed significant variability in approaches, emphasizing the need for standardized practices and increased awareness in the diagnosis and management of GIM and atrophic gastritis. image
引用
收藏
页数:9
相关论文
共 17 条
  • [11] The Japanese guidelines for gastric cancer screening
    Hamashima, Chisato
    Shibuya, Daisuke
    Yamazaki, Hideo
    Inoue, Kazuhiko
    Fukao, Akira
    Saito, Hiroshi
    Sobue, Tomotaka
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (04) : 259 - 267
  • [12] Index diagnoses of gastric intestinal metaplasia in the United States: patient characteristics, endoscopic findings, and clinical practice patterns at a large tertiary care center
    Parbhu, Sheeva K.
    Shah, Shailja C.
    Sossenheimer, Michael J.
    Fang, John C.
    Peterson, Kathryn A.
    Gawron, Andrew J.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [13] Risk of gastric cancer among patients with gastric intestinal metaplasia
    Shao, Liming
    Li, Peiwei
    Ye, Jun
    Chen, Jiamin
    Han, Yuehua
    Cai, Jianting
    Lu, Xinliang
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (07) : 1671 - 1677
  • [14] Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review
    Spence, Andrew D.
    Cardwell, Chris R.
    McMenamin, Una C.
    Hicks, Blanaid M.
    Johnston, Brian T.
    Murray, Liam J.
    Coleman, Helen G.
    [J]. BMC GASTROENTEROLOGY, 2017, 17
  • [15] TUKUITONGA CF, 1992, NEW ZEAL MED J, V105, P463
  • [16] World Health Organisation, GLOBOCAN 2020: The Global Cancer Observatory 2020
  • [17] Xia HHX, 2000, AM J GASTROENTEROL, V95, P114, DOI 10.1111/j.1572-0241.2000.01609.x